Industry News
Make Or Break For Cellular Tissues
May 18, 2012
Models developed to study liquids are used to investigate the mechanics of cellular tissues, which could further our understanding of embryonic development and cancer In a study about to be published in EPJ E¹, French physicists from the Curie Institute in Paris have demonstrated that the behaviour of a thin layer of cells in contact with an unfavourable substrate is akin... Read More
Lapatinib Combined With Cetuximab Overcomes Resistance In EGFR-Driven Tumors
May 18, 2012
Targeted therapies have been studied for years, but recent laboratory research is providing robust clues about drugs that might work better in combination, particularly in treating cancers that have become resistant to therapy. That kind of information is behind a novel clinical trial at Georgetown Lombardi Comprehensive Cancer Center that combines cetuximab and lapatinib... Read More
Positive Survival Trend Seen In Phase I Study Of Temsirolimus, Capecitabine
May 18, 2012
A phase I clinical trial examining the safety of combining temsirolimus and capecitabine in advanced malignancies suggests the two agents can be given safely to patients... Read More
More Genes Discovered In The Fight Against Breast Cancer
May 18, 2012
In a study published in Nature, researchers describe nine new genes that drive the development of breast cancer. This takes the tally of all genes associated with breast cancer development to 40. The team examined all the genes in the genomes of 100 cases of breast cancer... Read More
More Genes Discovered In The Fight Against Breast Cancer
May 18, 2012
In a study published in Nature, researchers describe nine new genes that drive the development of breast cancer. This takes the tally of all genes associated with breast cancer development to 40. The team examined all the genes in the genomes of 100 cases of breast cancer... Read More
Established Cancer Vaccine Works Better In Tandem With FDA-Approved Kidney Transplant Drug
May 18, 2012
A team from the Perelman School of Medicine and the Abramson Family Cancer Research Institute at the University of Pennsylvania found that the FDA-approved drug daclizumab improved the survival of breast cancer patients taking a cancer vaccine by 30 percent, compared to those patients not taking daclizumab. This proof-of-concept study is published this week in Science Translational Medicine... Read More
Established Cancer Vaccine Works Better In Tandem With FDA-Approved Kidney Transplant Drug
May 18, 2012
A team from the Perelman School of Medicine and the Abramson Family Cancer Research Institute at the University of Pennsylvania found that the FDA-approved drug daclizumab improved the survival of breast cancer patients taking a cancer vaccine by 30 percent, compared to those patients not taking daclizumab. This proof-of-concept study is published this week in Science Translational Medicine... Read More
Google Algorithm Finds Cancer Biomarkers
May 17, 2012
Seven proteins that can help physicians evaluate how aggressive a patient's cancer is and whether or not they should receive chemotherapy have been identified by German researchers... Read More
Racial Disparities Revealed In Prostate Cancer Surgery
May 17, 2012
Black prostate cancer patients may not be getting the same quality of care as white patients, according to a first-of-its-kind study by researchers at Henry Ford Hospital who found racial disparities in the results of surgery to remove diseased prostates... Read More
Teaching Hospitals With Fellowship Programs Have Less Radical Prostatectomy Complications
May 17, 2012
Patients who undergo radical surgery for prostate cancer may expect better results, on average, if they're treated in accredited teaching hospitals with residency programs, and better still if the hospitals also have medical fellowships, according to a new study by Henry Ford Hospital... Read More
Previous Page Next Page